|
|
|
This is the preliminary program for the 2007 Joint Statistical
Meetings in Salt Lake City, Utah.
|
|
|
The views expressed here are those of the individual authors and not necessarily those of the ASA or its board, officers, or staff. Back to main JSM 2007 Program page |
= Applied Session,
= Theme Session,
= Presenter
105
|
Mon, 7/30/07, 8:30 AM - 10:20 AM | CC-155 B |
| Statistical Issues in Oncology Trials - Contributed - Papers | ||
|
Biopharmaceutical Section, Biometrics Section |
||
| Chair(s): Dennis Cosmatos, Wyeth | ||
| 8:35 AM |
Modified Simon's Two-Stage Design with a Control Group —  Sunil K. Dhar, New Jersey Institute of Technology; Farid Kianifard, Novartis Pharmaceuticals; Michael Chen, TCM Groups, Inc.
|
|
| 8:50 AM |
Censored Data Within Phase III Oncology Studies Using Independent Radiology Review (IRC) Assessments — Pralay Mukhopadhyay, Bristol-Myers Squibb Company; Thomas Kelleher, Bristol-Myers Squibb Company
|
|
| 9:05 AM |
Estimate of Treatment Effect with Adjustment for Post-Discontinuation Treatment Resumption and Crossover and Other Therapies in Oncology Clinical Trials — Shengyan Hong, Eli Lilly and Company; Yanping Wang, Eli Lilly and Company
|
|
| 9:20 AM |
A Two-Stage Multinomial Randomized Selection Design in Phase II Oncology Trials — Zhiping Sun, Merck & Co., Inc.
|
|
| 9:35 AM |
An Adaptive Two-Stage Design for Active-Controlled Phase II Oncology Trial — Xiaoming Li, sanofi-aventis
|
|
| 9:50 AM |
Optimal Three-Outcome Designs for Screening Trials of New Agents — Vandana Mukhi, New York University; Yongzhao Shao, New York University
|
|
| 10:05 AM |
A Hybrid of Traditional Design and Isotonic Regression Method To Find MTD in Phase I Cancer Clinical Trials — Robert Bigelow, sanofi-aventis; Chunpeng Fan, University of Wisconsin-Madison; Richard Wu, sanofi-aventis; Hui Quan, sanofi-aventis
|
|
|
JSM 2007
For information, contact jsm@amstat.org
or phone (888) 231-3473. If you have questions about the Continuing Education program,
please contact the Education Department. |